Security key
03237H101
Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX)
CUSIP: 03237H101
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Shares outstanding
- 110,465,093
- Total 13F shares
- 114,149,853
- Share change
- +259,385
- Total reported value
- $1,586,300,754
- Put/Call ratio
- 21%
- Price per share
- $13.90
- Number of holders
- 169
- Value change
- +$10,726,688
- Number of buys
- 83
- Number of sells
- 87
Report period
Q1 2026
Institutions
169
Top holders
10
AMLX full security history
Previous quarter: Q4 2025
Amylyx Pharmaceuticals, Inc. SEC filings
Amylyx Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 03237H101
Recent filing periods:
Top shareholders of AMLX - Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
|
Company |
15%
from 13D/G
|
16,518,419
|
$199,542,502 | — | 31 Dec 2025 | |
| PERCEPTIVE ADVISORS LLC |
13D/G
13F
|
Company |
7.5%
|
8,284,882
|
$136,452,007 | -$10,993,445 | 31 Mar 2026 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
7.1%
from 13D/G
|
9,054,431
|
$109,377,525 | — | 31 Dec 2025 | |
| TCG Crossover GP II, LLC |
13D/G
|
— |
5.7%
|
6,243,812
|
$74,863,306 | $0 | 31 Dec 2025 | |
| Commodore Capital LP |
13D/G
13F
|
Company |
5.1%
|
5,650,000
|
$89,213,500 | $0 | 10 Nov 2025 | |
| Point72 Asset Management, L.P. |
13D/G
13F
|
Company |
2.6%
|
2,801,636
|
$38,074,233 | -$26,039,432 | 30 Sep 2025 | |
| Panacea Innovation Ltd |
13D/G
|
Panacea Venture Healthcare Fund II, L.P. |
2.6%
|
2,200,000
|
$11,792,000 | $0 | 31 Dec 2024 | |
| Adage Capital Management, L.P. |
13D/G
|
— |
2.5%
|
2,777,055
|
$33,296,889 | -$48,436,878 | 31 Dec 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
5.7%
|
6,243,812
|
$75,425,249 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.3%
|
5,804,912
|
$70,123,336 | — | 31 Dec 2025 | |
| Saturn V Capital Management LP |
13F
|
Company |
4.1%
|
4,496,487
|
$54,317,563 | — | 31 Dec 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
4%
|
4,465,872
|
$53,992,392 | — | 31 Dec 2025 | |
| First Light Asset Management, LLC |
13F
|
Company |
3%
|
3,355,539
|
$40,534,911 | — | 31 Dec 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
2.8%
|
3,109,503
|
$37,562,796 | — | 31 Dec 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
2.5%
|
2,777,055
|
$33,546,824 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
2.4%
|
2,613,221
|
$31,567,709 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
2.1%
|
2,359,824
|
$28,506,673 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2%
|
2,165,534
|
$26,163,536 | — | 31 Dec 2025 | |
| Almitas Capital LLC |
13F
|
Company |
1.9%
|
2,122,597
|
$25,640,972 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.9%
|
2,069,884
|
$25,004,199 | — | 31 Dec 2025 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
1.6%
|
1,750,000
|
$21,140,000 | — | 31 Dec 2025 | |
| 683 Capital Management, LLC |
13F
|
Company |
1.5%
|
1,650,000
|
$19,932,000 | — | 31 Dec 2025 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
1,513,148
|
$18,278,773 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.2%
|
1,336,010
|
$16,139,001 | — | 31 Dec 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
1.2%
|
1,333,236
|
$16,105,491 | — | 31 Dec 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
1.1%
|
1,200,096
|
$14,497,160 | — | 31 Dec 2025 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.91%
|
1,004,021
|
$12,128,574 | — | 31 Dec 2025 | |
| Logos Global Management LP |
13F
|
Company |
0.86%
|
950,000
|
$11,476,000 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.85%
|
937,764
|
$11,328,189 | — | 31 Dec 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.81%
|
890,356
|
$10,755,500 | — | 31 Dec 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.78%
|
858,684
|
$10,372,903 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.77%
|
845,408
|
$10,212,529 | — | 31 Dec 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
0.76%
|
835,684
|
$10,095,063 | — | 31 Dec 2025 | |
| Boxer Capital Management, LLC |
13F
|
Company |
0.72%
|
800,000
|
$9,664,000 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.7%
|
771,248
|
$9,316,092 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.65%
|
712,990
|
$8,612,919 | — | 31 Dec 2025 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.51%
|
565,140
|
$6,826,891 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.49%
|
543,323
|
$6,563,342 | — | 31 Dec 2025 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
0.48%
|
527,099
|
$6,367,356 | — | 31 Dec 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.46%
|
506,242
|
$6,115,403 | — | 31 Dec 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.45%
|
502,366
|
$6,068,581 | — | 31 Dec 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.45%
|
499,764
|
$6,037,149 | — | 31 Dec 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.41%
|
457,412
|
$5,525,537 | — | 31 Dec 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.37%
|
412,873
|
$4,987,506 | — | 31 Dec 2025 | |
| Cormorant Asset Management, LP |
13F
|
Company |
0.36%
|
400,000
|
$4,832,000 | — | 31 Dec 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.35%
|
381,760
|
$4,611,661 | — | 31 Dec 2025 | |
| Patient Square Capital LP |
13F
|
Company |
0.32%
|
350,000
|
$4,228,000 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.31%
|
344,968
|
$4,167,213 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.31%
|
344,401
|
$4,160,364 | — | 31 Dec 2025 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.3%
|
333,258
|
$4,025,757 | — | 31 Dec 2025 |
Institutional Holders of Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) as of Q1 2026
As of 31 Mar 2026,
Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) was held by
169 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
114,149,853 shares.
The largest 10 holders included
FMR LLC, BlackRock, Inc., PERCEPTIVE ADVISORS LLC, TCG Crossover Management, LLC, Commodore Capital LP, JANUS HENDERSON GROUP PLC, Saturn V Capital Management LP, VANGUARD CAPITAL MANAGEMENT LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., and First Light Asset Management, LLC.
This page lists
170
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
180
Q1 2026 holders
169
Holder diff
-11
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.